Sana Biotechnology (SANA) investor relations material

Strategic focus and technology platforms

• Emphasis on two main platforms: Hypoimmune for cell transplantation and Fusogen for in vivo gene delivery, targeting type 1 diabetes and CAR T therapies respectively.

• Hypoimmune aims to hide transplanted cells from immune rejection, with significant progress made.

• Fusogen platform enables targeted genetic payload delivery to specific cells, focusing on cell specificity and integration.

• Both platforms are positioned to address large unmet needs in type 1 diabetes and oncology/autoimmune diseases.

Type 1 diabetes program developments

• Advancing gene-modified, stem cell-derived islet therapy aiming for a functional cure: normal blood sugar, no insulin, no immunosuppression.

• IND filing and phase I study initiation targeted for this year, with early efficacy signals expected within months of dosing.

• Phase I will enroll 12–15 patients aged 18–65, aiming for insulin independence.

• Manufacturing scale-up and cost reduction are key for future commercialization, with pivotal readiness targeted for 2028.

• Recent data show long-term cell survival and function without immunosuppression in a human subject, supporting the approach.

In vivo CAR T platform progress

• SG293, targeting CD19, demonstrated robust CAR T generation and B-cell depletion in non-human primates without chemotherapy.

• Human dosing planned this year, with rapid efficacy readouts expected; expansion into lymphoma, other tumors, and autoimmune diseases anticipated if successful.

• Platform differentiates by targeting CD8 for entry, aiming for improved safety over CD3-based competitors.

• Success in either platform is not correlated, providing diversified risk.